Roka BioScience announces plans to price initial public sale of stock

BofA, Leerink are joint bookrunners; Cowen and Wedbush will assist

By Devika Patel

Knoxville, Tenn., May 21 - Roka BioScience, Inc. will conduct an initial public offering of its common stock with a 30-day greenshoe, according to an S-1 filing made Wednesday with the Securities and Exchange Commission.

BofA Merrill Lynch and Leerink Partners LLC are the joint bookrunning managers. Cowen and Co., LLC and Wedbush Securities Inc. are the co-managers.

Proceeds will be used for research and development.

The molecular diagnostics company is based in Warren, N.J. The company intends to list its common stock on the Nasdaq Global Market under the symbol "ROKA."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.